Removing Traditional
Limitations on
Administering Therapies

Halozyme’s ENHANZE® drug delivery technology is based on our patented recombinant human hyaluronidase enzyme , rHuPH20 to enable and optimize subcutaneous drug delivery for appropriate co-administered therapies.

With the technology, some biologics and compounds that are administered intravenously may instead be delivered subcutaneously, or under the skin, potentially providing a better experience for patients, and increasing health system efficiency by reducing administration time, injection pain and infusion site reactions.

For more information, download Delivering a Volume of Benefits.

Halozyme has collaboration agreements for the ENHANZE technology with Roche, Pfizer, Janssen, Baxalta, AbbVie, Eli Lilly, Bristol-Myers Squibb and Alexion.

For more information on partnering with Halozyme, please contact a member of the Business Development Team.



You are now leaving Halozyme is not responsible for or endorses the content of the linked site.